Halozyme Therapeutics, Inc. (HALO)
62.44
-0.44
(-0.70%)
USD |
NASDAQ |
Dec 09, 14:00
Halozyme Therapeutics EPS Diluted (Quarterly): 1.432 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Merck & Co., Inc. | 2.316 |
| ANI Pharmaceuticals, Inc. | 1.133 |
| Bristol Myers Squibb Co. | 1.079 |
| Twist Bioscience Corp. | -0.4491 |
| Aurinia Pharmaceuticals, Inc. | 0.232 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 175.22M |
| Revenue (Quarterly) | 354.26M |
| Total Expenses (Quarterly) | 179.04M |
| Enterprise Value | 8.203B |
| Gross Profit Margin (Quarterly) | 79.39% |
| Profit Margin (Quarterly) | 49.46% |
| Earnings Yield | 7.62% |
| Operating Earnings Yield | 9.41% |
| Normalized Earnings Yield | 7.619 |